Skip to main content Accessibility help
×
Home
  • Print publication year: 2009
  • Online publication date: October 2009

20 - Novel Analgesic Drug Delivery Systems for Acute Pain Management

from SECTION II - Clinical Analgesia

REFERENCES

1. Proksch E, Jensen JM. Skin as an organ of protection. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, eds. Fitzpatrick's Dermatology in General Medicine. 7th ed. New York, NY: McGraw-Hill; 2008;383–395.
2. Prausnitz MR, Bose VG, Lagner R, Weaver JC. Electroporations of mammalian skin: a mechanism to enhance transdermal drug delivery. Proc Natl Acad Sci USA. 1993;90:10504–10508.
3. Scheindlin S. Transdermal drug delivery: past, present, future. Mol Interven. 2004;4:308–332.
4. Grond S, Radbruch L, Lehmann KA. Clinical pharmacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 200:38–59.
5. Gourlay GK, Kowalski SR, Plummer JL, Cherry DA, Gaukroger P, Cousins MJ. The transdermal administration of fentanyl in the treatment of postoperative pain: pharmacokinetcs and pharmacodynamic effects. Pain. 1989;37:193–202.
6. Gourlay GK, Kowalski SR, Plummer JL, Cousins MJ, Armstrong PJ. The efficacy of transdermal fentanyl in the treatment of postoperative pain: a double-blind comparison of fentanyl and placebo systems. Pain. 1990;40:21–28.
7. Broome IJ, Wright BM, Bower S, Reilly CS. Postoperative analgesia with transdermal fentanyl following lower abdominal surgery. Anaesthesia. 1995;50:300–303.
8. Duthie DJ, Rowbotham DJ, Wyld R, Henderson PD, Nimmo WS. Plasma fentanyl concentrations during transdermal delivery of fentanyl to surgical patients. Br J Anaesth. 1988;60:614–618.
9. Grond S, Radbruch L, Lehmann KA. Clinical pharamacokinetics of transdermal opioids: focus on transdermal fentanyl. Clin Pharmacokinet. 200:38:59–89.
10. Holley FO, van Steennis C. Postoperative analgesia with fentanyl: pharmacokinetics and pharmacodynamics of constant-rate i.v. and transdermal delivery. Br J Anaesth. 1988;60:608–613.
11. Varvel JR, Shafer SL, Hwang SS, Coen PA, Stanski DR. Absorption characteristics of transdermally administered fentanyl. Anesthesiology. 1989;70:928–934.
12. Peng P, Sandler A. A review of the use of fentanyl in analgesia in management of acute pain in adults. Anesthesiology. 1999;90:576–599.
13. Frolich M, Giannotti A, Modell JH. Opioid overdose in a patient using a fentanyl patch during treatment with a warming blanket. Anesth Analg. 2001;93;647–648.
14. Food and Drug Administration. Fentanyl transdermal system approved for chronic pain. JAMA. 1990;264:1802.
15. Rowbotham MC, Davies PS, Verkempinck C, Galer BS. Lidocaine patch: double-blinded controlled study of a new treatment method for post-herpetic neuralgia. Pain. 1996;65:39–44.
16.Lidoderm (lidocaine patch 5%) [package insert]. Chadds Ford, PA: Endo Pharmaceuticals; 2006.
17. Galer, BS, Rowbotham MC, Perander J, Friedman E. Topical lidocaine patch 5% relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enrichment enrollment study. Pain. 1999;80:533–538.
18. Katz HP, Gammaitoni AR, Davis MW, Dworkin RH and the Lidoderm Patch Study Group. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med. 2002;3:324–332.
19. Meier T, Wasner G, Faust M, et al. Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain. 2003;106;151–158.
20. Nalamachu S, Crockett RS, Gammaitoni A, Gould AR, Errol M. A comparison of lidocaine patch 5% vs naproxen 500 mg twice weekly for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Medscape Gen Med. 2006;8:33.
21. Karmarkar A, Lieberman I. Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anesth. 2007;98:261–262.
22. Hines R, Keaney D, Moskowitz MH, Prakken S. Use of lidocaine patch 5% for chronic low back pain; a report of four cases. Pain Med. 2002;3:361–365.
23. Argyra E. 5% lidocaine patch in the treatment of neuropathic pain of diverse origin. [abstract]. Eur J Pall Care-Abstract book 9 Congress of the European Association for Palliative Care. 2003;80.
24. Devers A, Galer B. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain. 200:16(3):205–208.
25. Benoist JL. Gammaitoni AR. The 5% lidocaine patch reduces pain intensity in professional athletes with sports injury pain without significant systemic effects or cognitive and performance impairment. Arch Phys Med Rehab. 2005;86.e34.
26. Gammaitori AR, Davis MW. Pharmacokinectics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother. 2002;236–240.
27. Barbano RL, Hermann DN, Galer BS, et al. Effectiveness of lidocaine patch 5% in diabetic neuropathy patients with or without allodynia (2003) Abstract presented at: the 7th International Conference on the Mechanisms and Treatment of Neuropathic Pain; September 18–20; San Francisco, CA.
28. J. Gimbel M, Hale R, Linn BS, Galer, E. Kurkimilis E, Gammaitor AR. Lidocaine patch 5% in patients with acute/subacute chronic low back pain: Impact on pain intensity, pain relief, and pain interference with QOL (2003) Abstract presented at: the 22nd Annual Meeting of the American Pain Society; March 20–23; Chicago, IL.
29. Galer BS. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med. 2003;163:628.
30.Flector (diclofenac epolamine topical patch 1.3%), [package insert]. Sanbonmatsu, Kagawa, Japan: Teikoku Seiyaki Co, Ltd; 2007.
31. Galer BS, Rowbothman M, Perander J, Devers A, Friedman E. Topical diclofenac patch relieves minor sports injury pain: results of a multicenter controlled clinical trial. J Pain Symptom Manage. 2000;19:287–294.
32. Predel HG, Koll R, Pabst H, et al. Diclofenac patch for topical treatment of acute impact injuries: a randomised, double blinded, placebo controlled, mutlicenre study. Br J Sports Med. 2004;38:318–323.
33. Argarwal A, Gautam S, Gupta D, Singh U. Transdermal diclofenac patch vs eutectic mixture of local anesthestics for venous cannulation pain. Can J Anesth. 2007;54:196–200.
34. Reinhart DJ, Goldberg ME, Roth JV, et al. Transdermal fentanyl system plus im ketorolac for the treatment of postoperative pain. Can J Anaesth. 1997;44377–44384.
35. Miguel R, Kreitzer JM, Reinhart D, et al. Postoperative pain control with a new transermal fentanyl delivery system: a multicenter trial. Anesthesiology. 1995;83:470–477.
36. Fiset P, Cohane C, Browne S, et al. Biopharmaceutics of a new transdermal fenanyl device. Anesthesiology. 1995;83:459–469.
37. Hammell DC, Stolarczyk EI, Klausner M, et al. Bioconversion of Naltrexone and Its 3-O-Alkyl-Ester Prodrugs in a Human Skin Equivalent. J Pharm Sci 2005;94:828–836.
38. Viscusi ER, Witkowski TA. Iontophoresis: the process behind noninvasive drug delivery. Reg Anesth Pain Med. 2005;30:292–294.
39. Batheja P, Kaushik D, Hu L, Michniak-Kohn BB. Transdermal iontophoresis. Drug Deliv. 2007.
40. Curdy C, Kalia Y, Guy RH. Non-invasive assessment of the effects of iontophoresis on human skin in-vivo. J Pharm Pharmacol. 2001;52:769–777.
41.Ionsys (fentanyl iontophoretic transdermal system) [package insert]. Raritan NJ: Ortho-McNeil, Inc; August 2006.
42. Minkowitz HS. Fentanyl Iontophoretic Transdermal System: A Review. Techniques in Regional Anesthesia and Pain Management. 2007;11(1):3–8.
43. Gupta SK, Southam M, Santhyan G, Klausner M. Effect of current density on pharmacokinetics following continuous or intermittent input from a fentanyl electrotransport system. J Pharm Sci. 1998;87:976–981.
44. Gupta SK, Bernstein KJ, Noorduin H, van Peer A, Saythan G, Haak K. Fentanyl delivery from a electrotransport system. Delivery is a function of total current, not duration of current. J Clin Pharmacol. 1998;48:951–958.
45. Gupta SK, Sathyan G, Phipps B, Klausner M, Southam M. Reproducible fentanyl doses delivered intermittently at different time intervals from an electrotransport system. J Pharm Sci. 1999;88:835–841.
46. Sathyan G, Jaskowiak J, Evashenk M, Gupta S. Characterisation of the pharmacokinetics of fentanyl HCL patient-controlled transdermal system (PTCS): effect of current magnitude and multiple-day dosing, and comparison with IV fentanyl administration. Clin Pharmacokinet. 2005;44(suppl 1):7–15.
47. Camu F, Van Aken H, Bovill JG. Postoperative analgesic effects of three demand dose sizes of fentanyl administered via patent controlled analgesia. Anesth Analg. 1998;87:890–895.
48. Gupta SK, Hwang S, Southam M, Sathyan G. Effects of application site and subject-controlled demographics on the pharmacokinetics of fentanyl HCL patient-controlled transdermal system (PCTS). Clin Pharmacokinet. 2005;44:25–32.
49. Sathyan G, Zomorodi K, Gidwani S, Gupta SK. The effect of dosing frequency on the pharmacokinetics of a fentanyl HCL patient-controlled transdermal system (PCTS). Clin Pharmacokinet. 2005;44:17–24.
50. Panchal SJ, Damaraju CV, Nelson WW, Hewitt DJ, Schein JR. System-related events and analgesic gaps during postoperative pain management with the fentanyl iontophoretic transdermal system and morphine intravenous patient-controlled analgesia. Anesth Analg. 2007;105:1437–1441.
51. Evans C, Schein J, Nelson W, et al. Improving patient and nurse outcomes: a comparison of nurse tasks and time associated with two patient-controlled analgesia modalities using Delphi panels. Pain Manage Nurs. 2007;8:86–95.
52. Hartrick CT, Bourne MH, Gargiulo K, Damaraju CV, Vallow S, Hewitt DJ. Fentanyl iontophoretic transdermal system for acute-pain management after orthopedic surgery : a comparative study with morphine intravenous patient-controlled analgesia. Reg Anesth Pain Med. 2006;31(6):546–554.
53. Chelly JE, Grass J, Houseman TW, Minkowitz, Pue A. The safety and efficacy of a fentanyl patient-controlled transdermal system for acute postoperative analgesia: a multicenter, placebo-controlled trial. Anesth Analg. 2004;98:427–433.
54. Koo PJS. Postoperative pain management with a patient-controlled transdermal delivery system for fentanyl. Am J Health-Syst Pharm. 2005;62:1171–1176.
55. Viscusi ER, Reynolds L, Tait S, Melson T, Atkinson LE. Iontophoretic fentanyl patient-activated analgesic delivery system for post-operative pain: a double-blind, placebo-controlled trial. Anesth Analg. 2006;102:188–194.
56. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S. Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA. 2004;291:1333–1341.
57. Minkowitz HS, Rathmell JP, Vallow S, Gargiulo K, Damaraju CV, Hewitt DJ. Efficacy and safety of the fentanyl iontophoretic transdermal (ITS) and intravenous patient-controlled analgesia (IV PCA) with morphine for pain management following abdominal or pelvic surgery. Pain Med. 2007;8(8):657–668.
58. Viscusi ER, Siccardi M, Damarju CV, Hewitt DJ, Kershaw P. The safety and efficacy of fentanyl iontophoretic transdermal system compared with morphine intravenous patient-controlled analgesia for post-operative pain management: an analysis of pooled data from three randomized, active-controlled clinical studies. Anesth Analg. 2007;105:1428–1436.
59.Lidosite Topical System [package insert. Fairlawn NJ: Vyteris Inc; 2004.
60. Block BM, Liu SS, Rowlingson AJ Cowan AR, Cowan JR, Wu CL. Efficacy of postoperative epidural analgesia: a meta-analysis. JAMA. 2003;290:2456–2463.
61. Wu CL, Cohen SR, Richman JM, et al. Efficacy of postoperative patient-controlled and continuous infusion epidural analgesia versus intravenous patient-controlled analgesia with opioids: a meta-analysis. Anesthesiology. 2005;103:1079–1088.
62. Ready LB. Acute pain: lessons learned from 25,000 patients. Reg Anesth Pain Med. 1999;24:499–505.
63. Kim T, Murdande S, Gruber A, Kim S. Sustained-release morphine for epidural analgesia in rats. Anesthesiology. 1996;85:331–338.
64. Yaksh TL, Provencher JC, Rathburn ML, Kohn FR. Pharmacokinetics and efficacy of epidurally delivered sustained-release encapsulated morphine in dogs. Anesthesiology. 1999;90:1402–1412.
65. Viscusi ER, Kopacz D, Hartrick CT, Martin G, Manvalien G. Single-dose extended-release epidural morphine for pain following hip arthroplasty. Am J Therapeut. 2006;13:423–431.
66. Viscusi ER, Martin G, Hartrick CT, Forty-eight hours of post-operative pain relief after total hip arthroplasty with a novel, extended-release epidural morphine formulation. Anesthesiology. 2005;102:1014–1022.
67. Hartrick CT, Martin G, Kantor G, Koncelik J, Manvelian G. Evaluation of a single-dose extended-release epidural morphine formulation for pain after knee athroplasty. J Bone Joint Surg. 2006;88A:271–281.
68. Gambling D, Hughes T, Martin G., Horton W, Manvelian G for the Single-Dose EREM Study Group. A comparison of DepoDur, a novel, single-dose extended-release epidural morphine, with a standard epidural morphine for pain relief after lower abdominal surgery. Anesth Analg. 2005;100:1065–1074.
69. Carvalho B, Riley E, Cohen SE, et al, for the DepoDur Study Group. Single-dose, sustained-release epidural morphine in the management of postoperative pain after elective cesarean section: results of a multicenter randomized controlled study. Anesth Analg. 2005;100:1150–1158.
70.[package insert]. San Diego CA: SkyePharma Inc; 2007.
71. Angst MS, Drover DR. Pharmacology of drugs formulated with Depofoam: a sustained release drug delivery system for parenteral administration using mutlivesicular liposome technology. Clin Pharmacokinet. 2006;45:1153–1176.
72. Rathmell JP, Wu CL, Sinatra RS, et al. Acute post-surgical pain management: a critical appraisal of current practice, December 2–4, 2005. Reg Anesth Pain Med. 2006;31(4 suppl 1):1–42.